Drug Trial Radar · NCT02826486
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Last checked: Nov 19, 2026Latest source record: Aug 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Sep 2016
Primary completion
Sep 6, 2022
Study completion Sep 6, 2022
Sponsor
- Lead sponsor
- BioLineRx, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jul 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL-8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.
Conditions
- Metastatic Pancreatic Adenocarcinoma
Interventions
BL-8040Drug
BL-8040 subcutaneous (SC) injections
PembrolizumabDrug
Pembrolizumab will be given as a 30-minute IV infusion
ChemotherapyDrug
• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Assessed by Imaging According to RECIST 1.1 CriteriaTime frame: Change in response between screening, end of monotherapy (Day 5), end of cycle 2 (Day 28) and approximately every 63 days until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Locations
31 sites in 4 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
Honor Health
Scottsdale, Arizona
Ochsner Medical Center
New Orleans, Louisiana
Massachusetts General Hospital (MGH)
Boston, Massachusetts
Beth Israel Deaconess Medical Center (BIDMAC)
Boston, Massachusetts
DF/HCC
Boston, Massachusetts
Karmanos Cancer Center, Wayne State University
Detroit, Michigan
Washington University of St Louis
St Louis, Missouri
Atlantic Medical Group
Morristown, New Jersey
NYU Langone Health
New York, New York
Cornell Medical College
New York, New York
University of Rochester
Rochester, New York
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Virginia Mason Medical Center
Seattle, Washington
Rambam Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Rabin Medical Center
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Sourasky Medical Center
Tel Aviv, Israel
Samsung Medical Center
Seoul, South Korea
Hospital General Universitario de Elche
Alicante, Spain
Vall d'Hebron
Barcelona, Spain
Gregorio Marañón Hospital
Madrid, Spain
Hospital Universitario de Fuenlabrada
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
La Paz
Madrid, Spain
Hospitalario Universitario de Ourense
Ourense, Spain
Clinic Universidad de Navarra
Pamplona, Spain
University Hospital of Salamanca
Salamanca, Spain
Marques de Valdecilla de Santander
Santander, Spain
Hospital Universitari i Politècnic La Fe,
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.